UBS upgraded TransDigm Group Inc, now rated "Buy" from "Neutral," on stabilised aftermarket growth, margin expansion, and increased capital deployment.

The country's economy could expand at a faster pace this year compared to 2024 due to the typical boost from elections, ...

The model assumes a discounted rate of 9.0% and a target EBIT margin of 20%. The price target of €1,208 underscores the ...

Free cash flow for fiscal 2026 is anticipated between $2.075 billion and $2.175 billion, incorporating approximately $110 million-$120 million of restructuring-related outflows and a $130 million-$150 ...

Following the collapse of Credit Suisse, the Swiss bond market is undergoing a reshuffling. One player stands out: Deutsche Bank.

FEMSA's Q4 2024 earnings report reveals strong revenue growth, margin expansion, and a $5.3B capital return plan.

Chinese policymakers will likely adopt a more pro-growth stance and strengthen "extraordinary countercyclical measures" to ...

Cosette Pharmaceuticals Inc, which is backed by Avista Healthcare Partners and Hamilton Lane, has agreed to acquire Mayne Pharma, an Australian specialty pharmaceutical company, for $430 million.

Hear from the UBS Global Banking team on how AI is driving the market and where the next opportunities for AI-driven innovation with be. Tune in as Rob Ruple, UBS Sector Sales Specialist touches on ...

New capital requirements for UBS could be delayed by years after Switzerland’s finance ministry announced plans on Wednesday to shift key decisions to parliament, with a possible referendum pushing ...